This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Galectin Therapeutics’s 8K filing here.
Galectin Therapeutics Company Profile
Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.
Featured Articles
- Five stocks we like better than Galectin Therapeutics
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- AI Demand Sparks Opportunities for These 3 Nuclear Energy Leaders
- Stock Splits, Do They Really Impact Investors?
- TSMC: Long-Term Outlook Still Strong as Geopolitical Risk Rises
- What is the Shanghai Stock Exchange Composite Index?
- Uber’s NVIDIA Deal and Buybacks Signal Major Upside
